2.55% -0.012

Theriva Biologics Inc (TOVX)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Theriva Biologics Inc Stock (TOVX) Company Profile

Theriva Biologics Inc

Healthcare (1170)

Biotechnology (665)

301 417 4364

9605 Medical Center Drive, Suite 270, Rockville

Nächster Verdiensttermin

Neueste SEC-Einreichungen

TOVX's Discussions on Twitter

Vergleichen Sie TOVX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
TOVX Theriva Biologics Inc	0.458	3.50M	0	-18.35M	-19.20M	-1.16
ONC Beone Medicines Ltd Adr	258.27	26.01B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	445.85	114.30B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.3499	41.83M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	83.98	6.29B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	484.93	63.90B	14.09B	4.50B	2.96B	39.28

Theriva Biologics Inc Aktie (TOVX) Neueste Nachrichten

Finanzdaten der Theriva Biologics Inc-Aktie (TOVX)

Theriva Biologics Inc (TOVX)

Theriva Biologics Inc Stock (TOVX) Company Profile

Vergleichen Sie TOVX mit anderen Aktien

Theriva Biologics Inc Aktie (TOVX) Neueste Nachrichten

Theriva?? Biologics Announces Presentation of Data from Vcn-01 Retinoblastoma Phase 1 Clinical Trial At Asco 2025 - marketscreener.com

Theriva Biologics (TOVX) to Present Key Retinoblastoma Trial Dat - GuruFocus

Theriva™ Biologics Announces Presentation of Data from - GlobeNewswire

Breakthrough Cancer Drug VCN-01 Takes on Rare Pediatric Eye Cancer and Pancreatic Cancer at ASCO 2025 - Stock Titan

Synthetic Biologics stock plunges to 52-week low of $0.47 By Investing.com - Investing.com South Africa

Synthetic Biologics stock plunges to 52-week low of $0.47 - Investing.com Australia

Theriva Biologics: Q1 Earnings Snapshot - Midland Daily News

Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results - GlobeNewswire

Theriva Biologics (TOVX) Achieves Milestone in Pancreatic Cancer Trial | TOVX Stock News - GuruFocus

Theriva Biologics Posts Narrower Loss In Q1 - Nasdaq

Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results | TOVX Stock News - GuruFocus

Breakthrough: New Cancer Drug Shows Survival Benefits in Advanced Pancreatic Cancer Trial Results - Stock Titan

Theriva™ Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients - The Globe and Mail

Theriva Biologics’ (TOVX) Hold Rating Reiterated at Maxim Group - Defense World

Theriva Biologics Shares Plunge After Pricing $7.5M Offering: Retail Sentiment Still Strong - MSN

Theriva Biologics Completes $7.5 Million Public Offering - TipRanks

Theriva Biologics Announces Closing of $7.5 Million Public Offering | TOVX Stock News - GuruFocus

Theriva Biologics Closes $7.5 Million Public Offering to Advance Cancer Therapeutics - Nasdaq

Theriva Biologics Announces Closing of $7.5 Million Public Offering - GlobeNewswire

Theriva Biologics Inc (AMEX: TOVX) Shares Are Set To Rise By 2025 - Stocksregister

Theriva Biologics (TOVX) Faces Downgrade After Phase 2b Study Re - GuruFocus

Theriva Biologics (TOVX) Faces Downgrade After Phase 2b Study Results | TOVX Stock News - GuruFocus

TOVX: Theriva Biologics Downgraded by Maxim Group | TOVX Stock N - GuruFocus

This Coty Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday - Benzinga

Theriva’s VCN-01 improves survival in phase IIb pancreatic cancer trial - BioWorld MedTech

Theriva™ Biologics Announces Primary Endpoints for Efficacy - GlobeNewswire

Theriva Biologics sets terms for $7.5 million public offering By Investing.com - Investing.com South Africa

Transcript : Theriva Biologics, Inc.Special Call - marketscreener.com

Theriva?? Biologics Announces Primary Endpoints for Efficacy and Safety Achieved in Virage Phase 2B Clinical Trial of Vcn-01 with Gemcitabine/Nab-Paclitaxel in Newly-Diagnosed Metastatic Pancreatic Cancer Patients - marketscreener.com

Theriva Biologics Announces Pricing of $7.5 Million Public Offering - citybiz

Theriva Biologics (TOVX) Announces $7.5 Million Public Offering - GuruFocus

Theriva Biologics (TOVX) Announces $7.5 Million Public Offering | TOVX Stock News - GuruFocus

Theriva Biologics Announces Pricing of $7.5 Million Public Offering | TOVX Stock News - GuruFocus

Theriva Biologics Announces Pricing of Public Offering for $7.5 Million to Support Cancer Therapeutics Development - Nasdaq

Theriva Biologics sets terms for $7.5 million public offering - Investing.com

Theriva Biologics (TOVX) Reports Promising Phase 2b Trial Results for VCN-01 | TOVX Stock News - GuruFocus

Theriva™ Biologics Announces Primary Endpoints for Efficacy and Safety Achieved in VIRAGE Phase 2b Clinical Trial of VCN-01 with Gemcitabine/nab-Paclitaxel in Newly-Diagnosed Metastatic Pancreatic Cancer Patients - The Manila Times

Theriva Biologics (NYSEAMERICAN:TOVX) Stock Price Up 6.8% – Should You Buy? - Defense World

Theriva Biologics Announces Presentation of Data from the - GlobeNewswire

Major Clinical Trial Update: Theriva's SYN-004 Shows Promise in Transplant PatientsKey Data Revealed - Stock Titan

Synthetic Biologics stock plunges to 52-week low at $1.02 - Investing.com Australia

Synthetic Biologics stock plunges to 52-week low at $1.02 By Investing.com - Investing.com South Africa

Theriva Biologics Completes Enrollment For VIRAGE Trial, Topline Data Expected In Q2 2025 - Nasdaq

Theriva™ Biologics Announces Positive Outcomes from the Second Meeting of the Independent Data Monitoring Committee for VIRAGE, the Company’s Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Ad - GlobeNewswire

Cancer Drug Breakthrough: Independent Committee Confirms Positive Safety Data in Phase 2b Pancreatic Trial - Stock Titan

Theriva Biologics (NYSEAMERICAN:TOVX) Shares Down 1.4% – Should You Sell? - Defense World

Finanzdaten der Theriva Biologics Inc-Aktie (TOVX)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie TOVX